Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

A: TODAY, WE ARE USED TO SEEING SHAREHOLDERS use proxy battles to insert their representatives into the board of directors (eg. Medicines Company and Ariad). Further, the makeup of a typical company’s ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

ONE OF THE MOST IMPORTANT THINGS TO DO DURING THE TRANSITION is put aside your preconceived notions and listen. We all think we know a lot about our industry partners and other components of the ...

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and ...

Usama Malik, CEO of Fore Biotherapeutics, shares how his approach to screening and interviewing candidates has evolved from one focused on university degrees, references, and experiences, to one that ...

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule ...

The number of gene therapy candidates in development is growing rapidly, with many advancing toward late-stage trials. The majority of these therapies are based on viral vector delivery. While ...

More companies are adopting the “modality-independent” approach (i.e., agnostic to whether the drug is a chemical or a biologic) to finding a therapeutic, which is a shift from the previous pharma ...

Eamonn Hobbs brings decades of drug device innovation experience to helm Syncromune's promising Sync-T solid tumor therapeutic platform.